Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-05-05

FDA Approved: ETHOSUXIMIDE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)

View source ↗

Summary

FDA approved a supplemental application for Ethosuximide (PAI Pharma) to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ethosuximide (ethosuximide)

Snippet

SUPPL AP for ETHOSUXIMIDE (ETHOSUXIMIDE)